Contribute Try STAT+ Today

Here is some analysis and perspective, not to mention a few burning questions, about the Phase 2 data Eli Lilly disclosed on its experimental Alzheimer’s therapy donanemab on Saturday.

STAT earlier asked five independent scientists involved in Alzheimer’s research about the study; unsurprisingly, their opinions were quite mixed, with the data representing a Rorschah test for their views on Alzheimer’s drug development. The study was also published in the New England Journal of Medicine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • “argues that it might have been ARIA-induced patient dropouts and not the drug. ” I would argue the exact opposite. ARIA is a sign that amyloid is being removed & ApoE4 patients progress faster. Pts progressing faster allows more opportunity to separate tx effect of drug vs PBO. those ARIA droputs may have hurt the efficacy, and may be the reason that the curves stopped separating

Comments are closed.